Aplicación Intralesional del Interferón alfa 2bHr cubano (Heberon Alfa R？) en el tratamiento de las verrugas genitales

introduction: the genital condyloma is the more frequent clinical expression or the human papilloma virus. from the available alternative of treatment there is not one of election and totally effective. objective: to describe the safety and the effect of recombinant alfa-interferon in treatment of genital warts. methods: a quasi-experimental study was conducted in 216 women and in 111 men. the above mentioned interferon was applied in the basement of warts at a dose of 10 millions of international units weekly during 8-16 weeks. patients were seen in the "ramón gonzález coro" gynecology and obstetrics hospital of la habana from march, 2009 to june, 2011. in each application the adverse events were reported, estimating its frequency distribution. the objective response was assessed according to the percentage of reduction of the sum of the great diameters at 4, 8 and 16 weeks after the application. recurrence was assessed at 24 months using the kaplan-meier curve. results: there was response to treatment in the 81.5 % of patients. more than 60 % had a total response where only the 11.1 % were recurrent. the more frequent adverse events were: fever, headache and chivers of slight or moderate intensity. conclusions: the application of interferon around injury may be considered an safe and effective alternative in treatment of genital warts.